Direct Antimicrobial Susceptibility Testing of Positive Blood Cultures: A Comparison of the Accelerate Pheno™ and VITEK® 2 Systems

Jack G. Schneider¹*, James B. Wood¹, Nathan W. Smith², Christopher L. Emery³, Thomas E. Davis³, John J. Manaloor¹, Brittany Bocian⁴, Bryan H. Schmitt³

¹Ryan White Center for Pediatric Infectious Diseases and Global Health, Indiana University School of Medicine, Indianapolis, Indiana, USA
²Accelerate Diagnostics, Inc., Tucson, Arizona, USA
³Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
⁴Indiana University Health, Methodist and University Hospitals, Indianapolis, Indiana, USA

*Corresponding author. Dr. Jack G. Schneider; Emerson Hall, Suite 421, 545 Barnhill Drive, Indianapolis, IN 46202, USA. Tel: 317-274-7936; Fax: 317-274-1587; E-mail: jgschnei@iu.edu

Running Title: Susceptibility Testing in Gram-Negative Bloodstream Infections

This is the author's manuscript of the article published in final edited form as:

ABSTRACT

Objectives: To compare the performance and time-to-result (TTR) for antimicrobial susceptibility testing (AST) of positive blood cultures (PBC) using the Accelerate Pheno™ system (AXDX) and both a direct VITEK® 2 card inoculation workflow (DV2) and traditional FDA-approved VITEK® 2 workflow using subcultured isolates (V2).

Methods: Patient samples with monomicrobial Gram-negative rod bacteremia were tested on AXDX and DV2 in tandem, and compared to V2 AST results. Categorical agreement (CA) errors were adjudicated using broth microdilution. Instrumentation times and AST TTR were compared.

Results: AXDX and DV2 had a CA of 91.5% and 97.4%, respectively, compared to V2. Post-adjudication, AXDX, DV2, and V2 had CA of 94.7%, 95.7% and 96.5%, respectively. Instrument run times were 6.6 h, 9.4 h, and 9.2 h, and AST TTR were 8.9 h, 12.9 h and 35.5 h, respectively.

Conclusions: AXDX and DV2 AST is fast and reliable, which may have significant antimicrobial stewardship implications.
Introduction

Early recognition of sepsis and initiation of targeted antibiotic therapy is crucial in the treatment of Gram-negative rod (GNR) bacteremia, as mortality increases for each hour of delay in effective antibiotic therapy (Kang et al., 2005; Kumar et al., 2006). Additionally, the increasing incidence and complexity of GNR antimicrobial resistance mechanisms (Peleg and Hooper, 2010; Meropol et al., 2018) has necessitated urgent improvement in fast antimicrobial susceptibility testing (AST).

Traditional laboratory methods for AST often take up to 48 hours from detection of a pathogen in blood culture. This process generally involves utilizing commercial systems to incubate blood in liquid medium, Gram staining, then sub-culturing signal-positive samples onto solid media until visible colonies form (Romero-Gómez et al., 2012; Schneiderhan et al., 2013; Machen et al., 2014; Chen et al., 2008). Automated systems, such as the VITEK® 2 system, expedite the reporting of AST profiles, but the traditional U.S. Food and Drug Administration (FDA) cleared VITEK® 2 system workflow (V2) still requires isolation of bacterial colonies for testing (Funke et al., 1998). However, without isolation of bacteria, utilizing a direct card inoculation VITEK® 2 workflow (DV2) for AST testing (Romero-Gómez et al., 2012; Machen et al., 2014; Ling et al., 2003; Jo et al., 2016; Barnini et al., 2016; Bazzi et al., 2017) improves reporting times for microbe identification (ID) and AST results. Despite this potential advantage, the DV2 method is under-studied, remains labor intensive, and is not cleared in the United States for in vitro diagnostic use by the FDA.

Additionally, in an effort to improve ID/AST reporting times, there have been an increasing number of novel, culture-independent fast technologies developed. The Accelerate Pheno™ system (AXDX), is one such technology that uses morphokinetic cellular analysis to provide fast
AST results directly from positive blood cultures (PBC) (Accelerate Diagnostics, Inc., 2018). The performance and timing of AST results compared to the VITEK® 2 system, including V2 and DV2 workflows, has previously not been directly evaluated.

Thus, the aim of this study was to compare the performance of AXDX and the VITEK® 2 system, including both V2 and DV2 workflows, for AST results of clinical samples and isolates from patients with GNR bacteremia. Secondarily, we assessed the total instrumentation times for testing commonly isolated GNRs among all three methods, along with time to results (TTR) for AST.

**Materials and Methods**

**Study Design and Population**

A prospective study comparing AST performance and TTR of AXDX (software version 1.3.1.15, Accelerate Diagnostics, Inc., Tucson, AZ) with both V2 and DV2 (VITEK® 2 XL system, BioMérieux, Marcy-l’Étoile, France) workflows for samples of GNR bacteremia was conducted at the Indiana University Health Pathology Laboratory (Indianapolis, IN). Patients seen at any of the Indiana University Health Hospitals, including Riley Hospital for Children, from September to December 2017 were eligible for inclusion if PBC indicated monomicrobial GNR bacteremia. Exclusion criteria for the performance evaluation were polymicrobial samples, AXDX or VITEK® 2 AST non-report, monomicrobial Gram-positive or off-panel organisms, unconfirmed/mismatched ID results, replicate samples or non-viable samples.

**Sample Testing**

Patient blood samples were collected using either aerobic, anaerobic, or pediatric blood culture bottles and incubated in the BACTEC® FX blood culture monitoring system (Becton Dickinson,
Franklin Lakes, New Jersey). All PBC demonstrating monomicrobial GNRs by Gram stain were tested on the AXDX system with the Accelerate PhenoTest™ BC kit and by DV2 for AST in parallel. Three AXDX testing modules were made available for use during this investigation, such that a maximum of three positive blood cultures could be tested simultaneously. For DV2, bacterial cell suspensions were made by pelleting bacteria from broth in serum separator tubes and resuspending the pellets in saline. VITEK® 2 GN73 cards were inoculated with cell suspensions adjusted to a turbidity approximating a 0.5 McFarland standard. All AXDX and DV2 AST outcomes were compared with V2 results obtained from testing isolated colonies of bacteria per standard laboratory protocol (Figure 2). All potential ESBL-producing isolates were initially flagged on the VITEK® 2 system and confirmed using the CLSI ESBL disk diffusion test from isolated colonies (Clinical and Laboratory Standards Institute, 2016).

**Performance Comparison & Adjudication Testing**

Identification was carried out using our available laboratory ID methods - MALDI Biotyper® system (Bruker Daltonics, Fremont, CA), VERIGENE® system (Luminex Corporation, Northbrook, IL) and AXDX. Monomicrobial GNR samples with concordant species identification between these identification modalities were included in AST performance analysis. However, ID performance analysis was outside the scope of this study. Samples reporting AST results for each of the three methods under investigation were included in performance analysis: AXDX, DV2 and V2. Using V2 as the initial comparator, calculations of essential agreement (EA), categorical agreement (CA), minor errors (MiE), major errors (ME), and very major errors (VME) for AXDX and DV2 were performed. CA was defined as results of susceptible, intermediate, or resistant that matched between compared methods based on 2016 CLSI minimum inhibitory concentration (MIC) breakpoints (Clinical and Laboratory Standards
Institute, 2016) for the identified species. EA was defined as agreement of MICs within ±1 doubling dilution between compared methods. A VME occurred when a sample was called resistant by the comparator and susceptible by the test method. A ME occurred when a sample was called susceptible by the comparator and resistant by the test method. A MiE occurred when a sample was intermediate by one method and susceptible or resistant by the other method.

Samples that did not have the same categorical result (S, I or R) across all three of our laboratory methods (AXDX, DV2 and V2) were adjudicated in a reference laboratory using broth microdilution (BMD) as a gold standard method for AST (van Belkum and Dunn, 2013; Food and Drug Administration, 2009). Frozen isolates were shipped to a reference laboratory for BMD testing once initial laboratory testing was completed and technologists were blinded to all results. BMD discrepancy testing was performed in triplicate, with the modal MIC reported as the adjudicating result. These results were used to generate a hybrid adjudication set (V2/BMD), which was also compared to AXDX, DV2 and original V2 results.

**Timing Comparison**

Total instrumentation times for commonly isolated GNRs among all three methods were compared, along with TTR for AST from time of blood culture positivity. Technologist hands-on time was included in TTR from time of blood culture positivity, but not included in instrumentation run time calculations (Figure 2). Additionally, adjustments for delays in results reporting from the laboratory to clinicians were not included in the timing calculations.

**Statistical Analysis**

Statistical analyses were performed with SciPy, (Jones et al., 2001) using the Python programming language. (Oliphant, 2007) Statistical analyses comparing independent continuous
variables (e.g. instrument run time to AST between all three modalities) were performed using the two-sided Mann Whitney U test. (Mann and Whitney, 1947) Fisher’s exact testing was performed when comparing discrete contingency tables (e.g. counts of errors in CA between modalities). Computed probability (p) of less than a significance level (α) of 0.05 was considered statistically significant. Where relevant, mean (μ) and standard deviation (σ) were noted.

Results

Microbiology Results

A total of 175 samples were collected. After excluding 44 samples (12 polymicrobial, 15 AST non-reports [11 AXDX, 4 V2], 9 off-panel organisms, 3 mismatched IDs, 3 replicate samples, 2 Gram-positive organisms, and 1 non-viable sample), a total of 131 samples including 17 seeded isolates (non-patient samples), 30 pediatric (age ≤21) clinical samples, and 84 adult (age >21) clinical samples from patients with monomicrobial GNR bacteremia were included in the AST performance evaluation (Figure 1). *E. coli* and *Klebsiella* spp. were the most frequently isolated GNRs (63 and 29 isolates respectively). Twelve percent (16/131) of the organisms were ESBL producers. Nine organisms not present on the AXDX ID panels made up 5.5% of total monomicrobial GNR cultures tested (prior to their exclusion in the analyzed dataset) and included one each of the following organisms: *Bacteroides fragilis*, *Salmonella* spp., *Shewanella* spp., *Dialister* spp., *Bacteroides thetaiotaomicron*, *Burkholderia gladioli*, *Pantoea calida*, *Achromobacter xylosoxidans*, and *Aeromonas* spp.

Comparison Results
A total of 131 pathogens were isolated and produced AST results on all three modalities. 1191 AST combinations were analyzed with AXDX having an overall CA of 93.4% compared to V2. AXDX had three VMEs (1 ampicillin-sulbactam, 1 piperacillin-tazobactam, 1 cefepime) compared to V2 (Table S1). When comparing DV2 to V2, there was 97.4% categorical agreement, with seven VMEs, including three each for cefepime and ceftazidime (Table S1). Of the 232 resistant combinations adjudicated by BMD, DV2 called thirteen of these susceptible (5.6% VME rate; 7 cefepime, 5 ceftazidime, 1 aztreonam), V2 called six susceptible (2.6% VME rate; 1 piperacillin-tazobactam, 2 cefepime, 2 ceftazidime, 1 aztreonam), compared to two on AXDX (0.9% VME rate; 2 piperacillin-tazobactam) (Table S2). For MEs, AXDX had 12 MEs compared to V2. AXDX MEs decreased to 4 when compared to BMD adjudicated results.

On further analysis, there were 63 errors (5.3%) on AXDX compared to BMD adjudicated results (Table S2). Of these, AXDX called 14 more susceptible than adjudicated (i.e. AXDX called intermediate when adjudication called resistant, or AXDX called susceptible when adjudication called resistant or intermediate), while the remaining 49 were called more resistant than adjudicated (Figure 3 (c)). AXDX was 3.5 times (49/14) more likely to have an error on the side of resistant if an actual error was determined. Conversely, V2 (using isolated colonies) had 42 errors (3.5%) compared to BMD adjudicated results. Of these, 29 were called more susceptible than adjudicated, while the remaining 13 were called more resistant. V2 was observed to be 2.2 times (29/13) more likely to have an error on the side of susceptible if an error was determined. Overall, AXDX was observed to have a 1.8% higher rate of errors compared to V2 (or 1.5 times the number of V2 errors). When in error AXDX is more likely to overcall resistance compared to V2, which tended to overcall susceptibility (p<0.001) from our dataset (Figure 3).
When comparing AXDX with DV2, errors from AXDX remained the same as previously listed, while DV2 had a total of 51 errors (4.3% of all AST combinations) compared to BMD adjudicated results (Table S2). Of these, 46 were called more susceptible than adjudicated results, while the remaining five were called more resistant. DV2 was observed to be 9.2 times (46/5) more likely to have an error on the side of susceptible if an error was determined. Overall, AXDX was observed to have a 1.0% higher rate of errors compared to DV2 (or 1.3 times the number of DV2 errors). Similarly, however, AXDX is more likely to overcall resistance compared to DV2 which tended to overcall susceptibility (p<0.001) (Figure 3 (c)). Finally, DV2 was observed to have a 0.8% higher rate of errors compared to V2 (or 1.1 times the number of V2 errors). As stated before, DV2 is 9.2 times (46/5) and V2 is 2.2 times (29/13) more likely to have an error on the side of susceptible if an error is determined. While both methods tended to overcall susceptibility, there was a significant difference between the ratio of errors between these two modalities (p=0.016) (Figure 3).

**ESBL producing organisms**

Twelve percent (16/131) of samples were found to be ESBL producers (two from seeded isolate samples, 14 from fresh patient samples). For these isolates, AXDX had an overall CA of 89.9%, while DV2 had a CA of 90.6% compared to V2 (Figure S2 (a)). CA was 85.5%, 91.2% and 92.5% for DV2, V2 and AXDX, respectively, against BMD adjudicated discrepancy results (Figure S2 (b)). Overall, there was still a tendency for DV2 to overcall susceptibility compared to AXDX (p=0.003). The effect of V2 to overcall susceptibility against AXDX was less pronounced (p=0.09) (Figure S1 (c)).

**Timing/Workflow Results**
Mean time to AST result from positive blood culture was 8.9 h, 12.9 h and 35.5 h for AXDX, DV2 and V2, respectively (Figure 4). Mean instrument run time for these methods for all samples, from time of set-up to time of AST result was 6.6 h, 9.4 h and 9.2 h for AXDX, DV2 and V2, respectively (Figure 5). For Pseudomonas aeruginosa, mean instrument run time for AXDX was 6.5 h, with longer run times for DV2 and V2, at 12.2 h, and 12.0 h respectively. Despite highly variable organism growth time from time of positivity as shown in the culture-dependent V2 workflow ($\sigma=7.65$ h for all samples, Figure S1), AXDX instrument run time for AST was also consistent ($\sigma=0.05$ h) compared to DV2 ($\sigma=1.5$ h) and V2 ($\sigma=1.6$ h) (Figure 5). Finally, DV2 and V2 workflows collectively required approximately 45 minutes of hands-on technologist preparation time, compared to AXDX workflow which was approximately 3 minutes (Figure 2).

**Discussion**

Relative to traditional modalities such as the V2 workflow, both AXDX and DV2 are fast and reliable for testing GNR’s from positive blood cultures. When compared against reference BMD, AXDX tends to overcall resistance, while the VITEK® 2 system (both DV2 and V2 workflows) tends to overcall susceptibility. Additionally, AST instrument run time by the VITEK® 2 system (both DV2 and V2 workflows) is variable, especially with *Pseudomonas aeruginosa*, compared to AXDX, which has more consistent AST instrument run times.

Overall, improper use of broad-spectrum antimicrobial therapy leads not only to an increase in antimicrobial resistant organisms (Kang et al., 2005; Tamma et al., 2017; Battle et al., 2017), but can also increase hospital length of stay, invite secondary infections, and result in additional costs to patients and health systems (Baggs et al., 2018). With the advent of faster phenotypic AST technologies, including the AXDX system, there is potential to significantly improve time
to diagnosis and initiation of appropriate antibiotics, including de-escalation, which has been associated with improved clinical outcomes (Raman et al., 2013; Cremers et al., 2014). Similar to other studies (Brazelton de Cárdenas et al., 2017; Charnot-Katsikas et al., 2018; Lutgring et al., 2018; Pantel et al., 2018; Pancholi et al., 2018; Marschal et al., 2017; Sofjan et al., 2018; Descours et al., 2018; Giordano et al., 2018), we found that AXDX provided reliable results for AST, which is comparable to other standard testing such as molecular, proteomics-based, and conventional phenotypic methods (i.e. VITEK® 2 system). This is the first study, however, comparing AXDX AST results directly to the less studied and non-FDA cleared direct inoculation VITEK® 2 system workflow (DV2), as well as to directly compare AXDX AST performance to both DV2 and V2 workflows on the VITEK® 2 system against reference methods (i.e. BMD).

Although DV2 remains understudied and is not currently FDA-cleared, it has been utilized and validated for clinical testing in medical laboratories in the U.S. and Europe (De Angelis et al., 2019). Given the significant decrease in time to result for AST with AXDX and DV2, we felt it prudent to explore these two methods further. When comparing AXDX directly to DV2 for GNR bacteremia, AXDX was observed to have a higher incidence of errors (1.3 times the number of DV2 errors). Despite these errors, however, AXDX was more likely to overcall resistance compared to DV2 (including ESBL isolates), which tended to overcall susceptibility. These overall AST tendencies also applied to testing directly between V2 and AXDX, although not as pronounced. Based on our dataset, both DV2 and V2 workflows had a tendency to overcall susceptibility, specifically with cefepime and ceftazidime (7 and 5 VMEs, respectively for DV2; 2 VMEs each for V2), while AXDX tended to overcall susceptibility for piperacillin-tazobactam (2 VMEs) and notably had 3 MEs for ampicillin-sulbactam. As outlined in the results section, it
is important to note that despite AXDX having 12 MEs and 21 MEs compared to V2 and DV2, respectively, these MEs decreased to 4 when compared to BMD adjudicated results. Furthermore, the DV2 workflow only had 7 VMEs when directly compared to V2, but nearly doubled that number post-adjudication (13 VMEs). In light of these notable AST patterns, future studies comparing clinical outcomes between AXDX and V2 are needed and planned.

Interestingly, despite DV2 having the capability of decreasing average time to result compared to V2 (12.9 h to 35.5 h), *P. aeruginosa* isolates tended to have a noticeably longer time to result for both VITEK® 2 methods (DV2: 15.1 h; V2: 40.4 h), including instrument run times (DV2: 12.2 h; V2: 12.0 h) compared to 6.6 h for AXDX. The true clinical significance of these time differences is unknown and will need to be studied further. It is important to mention, however, instances in which alternative comparator methods for complete AST were recommended by AXDX on the 175 enrolled samples. These instances include polymicrobial specimens producing at most AST for one organism on AXDX (12 samples, 6.9%) and AST non-reportable results on AXDX (n=11, 6.3 %). Additionally, nine samples were ‘off-panel’ organisms not identified by AXDX (5.1%) and DV2/V2 results terminated on another four enrolled samples (2.3%), requiring alternative AST comparator methods (Etests) to be performed in the laboratory. Consequently, like other fast diagnostics, AXDX and DV2 will not be able to replace traditional modalities for all AST combinations, particularly for off-panel or polymicrobial cultures (Lutgring et al., 2018; Pancholi et al., 2018; Bard and Lee, 2018; Özenci and Rossolini, 2019).

As with any novel diagnostic technology, cost-effectiveness and impact on clinical care must be considered. Though AXDX has shown itself to be a fast and reliable test for ID and AST, cost is a major limitation (Giordano et al., 2018). To that end, AXDX, as with any new, fast diagnostic
technology, may prove of greatest benefit to institutions possessing laboratories with multiple shifts and established antimicrobial stewardship teams capable of implementing clinical changes in a timely manner. Additionally, AXDX currently has a lower testing capacity compared to VITEK® 2. Our study utilized three AXDX modules, allowing for simultaneous testing of up to three samples, without any delays in set-up times during our study period, while the VITEK® 2 XL system used in this study could test up to 120 samples simultaneously.

From a laboratory workflow standpoint, AXDX did substantially reduce overall “hands-on” time for laboratory technologists, with the potential to decrease setup and processing time from nearly 45 minutes when combining DV2 and V2 workflows to approximately 3 minutes for AXDX. However, other techniques such as VITEK® 2 inoculation after short term incubation on solid medium from positive blood cultures (SIV2), which was not tested in our study, also provides reliable AST with minimal preparation and cost expenditure (Idelevich et al., 2014; Ha et al., 2018). Interestingly, Idelevich et al. reported SIV2 time to AST result from positive culture of 11.2 h (Idelevich et al., 2014), fitting between AXDX and DV2 times (8.9 h and 12.9 h respectively) in our study. SIV2 is another method that may be a valuable alternative to traditional methods. As novel, fast diagnostic technologies continue to evolve, further investigation into the impact on laboratory workflows, clinical decision making, and ultimately patient outcomes will be required across a variety of clinical settings to fully understand the utility of these tests.

This study has several limitations. First, our sample size and prevalence of resistance phenotypes are relatively low as it only includes GNR isolates sourced predominantly from our patient population. While this does limit the power and generalizability of the study, these isolates represent the clinically relevant pathogens in the diverse population at our institution. In
addition to sourcing samples of Gram-positive bacteremia, future studies may seek a subset of resistant samples, sourced from isolate banks, to improve understanding of performance in more resistant populations. Furthermore, the increasing complexity of antimicrobial resistance (Kang et al., 2005; Peleg and Hooper, 2010; Bard and Lee, 2018; Özenci and Rossolini, 2019; Perez et al., 2014; Barlam et al., 2016), along with the pressing, unmet needs in pathogen diagnostics (Blaschke et al., 2015) for GNR’s emphasize the importance of these pathogens. Second, polymicrobial samples as indicated by Gram stain (~10% of all PBCs) were excluded due to limitations on AXDX producing AST for all pathogens in these samples and DV2 results being invalid (Lutgring et al., 2018; Marschal et al., 2017). Furthermore, the lack of polymicrobial infections being tested (in addition to excluding Gram-positive BSI’s) may have increased the performance of AXDX, DV2, and V2 with respect to other studies. Third, our study site is a quaternary referral center with 24/7 testing capabilities, including a stewardship team with the capability of acting on results during all shifts of the day. Therefore, the potential clinical benefits of our findings are less generalizable to healthcare settings who do not have 24 hour a day availability for testing. These findings will have the greatest impact in locales with similar practices and resources to our study site. Finally, the antibiotic panels used for comparison studies among all three modalities are in no way complete or specific for each organism or clinical condition. As a result, it is difficult to deduce whether trends to overcall susceptibility or resistance would translate to better or worse clinical outcomes.

In conclusion, our findings showed that AST by AXDX and DV2 from PBCs with monomicrobial GNRs are fast and reliable, which may have significant implications for patient outcomes and antimicrobial stewardship. GNR bacteremia treatment continues to be costly, especially for high-risk patients, and infection can sometimes prove fatal. Consequently, the
continued research into how AST results from current technologies are utilized, and developing innovative new diagnostic modalities to acquire even faster AST TTR provides optimism for future success in combating further development of antimicrobial resistance. To evaluate the true clinical impact, studies directly comparing these three methods and how each one affects clinical decision making and patient outcomes are needed.

**Acknowledgements**

*Special thanks to the following:

-Medical Technologist Mike Rayl, and all other medical laboratory scientists at the Indiana University Health Pathology laboratory who assisted with set up and data acquisition

-Vera Winn, Director of Clinical Microbiology and Molecular Pathology at Indiana University Health Pathology Laboratory, for technical support and clinical bench space

-John Prichard and Christina Chantell from Accelerate Diagnostics, Inc. for technical support and manuscript preparation, respectively

**Funding**

*This study was supported by internal funding by the Department of Pathology and Laboratory Medicine through the Indiana University School of Medicine. Accelerate Diagnostics, Inc. provided the Accelerate Pheno™ system modules and half of the kits used in the study.*
Accelerate Diagnostics, Inc. was not involved in study design, data collection, or data
interpretation.

Transparency Declarations

*N.W.S has stock options and is an employee of Accelerate Diagnostics, Inc. N.W.S was
involved in data management, figure design, and manuscript preparation. J.G.S has received
research grant support from Accelerate Diagnostics, Inc. B.H.S is a principal investigator in
research studies for Accelerate Diagnostics, Inc., which do not include the assay compared in
this study. All other authors: none to declare.

*BMD adjudication studies were performed by the Discrepancy Laboratory at Accelerate
Diagnostics, Inc. Discrepant results were identified by the Indiana University Health Clinical
Microbiology Laboratory. Technologists performing confirmatory testing were blinded to all
results.

References


2. Baggs J, Jernigan JA, Halpin AL, Epstein L, Hatfield KM, McDonald LC. Risk of
   subsequent sepsis within 90 Days after a hospital stay by type of antibiotic exposure. Clin
   Infect Dis 2018;66(7):1004-12.


Figure 1. Flow diagram of study design and population inclusivity criteria

**Abbreviations:** AST=antimicrobial susceptibility testing; AXDX=Accelerate Pheno™ system; DV2=direct inoculation VITEK® 2; ESBL=extended spectrum beta-lactamase; ID=microbe identification; MALDI=matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; V2=traditional VITEK® 2.
Figure 2. Laboratory AST methodologies, including AXDX, DV2, and V2 workflows.
Figure 3. Analysis of categorical agreement. (a) Comparison between initial laboratory method results for AXDX and DV2 against V2. (b) Comparison between laboratory results rescored against V2/BMD adjudicated results. (c) Comparison of errors tending more resistant or more susceptible than V2/BMD adjudicated results.
Figure 4. Mean time to complete AST from blood culture positivity by method.
Figure 5. Mean instrument run time to complete AST by method

Computed probability (p) using Mann-Whitney U Test only shown on pair-wise combinations of AST methods in the 'All Samples' category and in 'PAE' category, not computed on other combinations.

Abbreviations: ABA=A. baumannii; AST=antimicrobial susceptibility testing; CT=C. trachomatis; ECO=E. coli; ENT=Enterobacter spp.; KLE=Klebsiella spp.; PAE=P. aeruginosa; PRO=Proteus spp.; SMA=S. marcescens; σ=standard deviation.
Positive Blood Culture & Gram Stain

Vortex & Place Sample into Vial
- Load Accelerate Pheno™ System
  - AXDX ID/AST Result

Centrifuge Sample
- Resuspend Pellet
  - Inoculate GN73 Card
    - Load VITEK® 2 System
      - DV2 AST Result

Subculture** & Incubate Overnight
- Prepare Isolate Suspension
  - Inoculate GN73 Card
    - Load VITEK® 2 System
      - V2 AST Result

*Hands-on workflow preparation time.
**Included in ~30 min hands-on time for DV2
Figure 2

### a) AXDX vs. V2

<table>
<thead>
<tr>
<th></th>
<th>S</th>
<th>I</th>
<th>R</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AXDX</td>
<td>891</td>
<td>4</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>33</td>
<td>10</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>19</td>
<td>211</td>
<td></td>
</tr>
</tbody>
</table>

CA = 93.4%
VME = 1.4%
ME = 1.3%
MIE = 5.4%

### b) AXDX vs. V2/BMD

<table>
<thead>
<tr>
<th></th>
<th>S</th>
<th>I</th>
<th>R</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AXDX</td>
<td>892</td>
<td>4</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>29</td>
<td>14</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>16</td>
<td>222</td>
<td></td>
</tr>
</tbody>
</table>

CA = 94.7%
VME = 0.9%
ME = 0.4%
MIE = 4.8%

### c) AXDX vs. V2/BMD

<table>
<thead>
<tr>
<th></th>
<th>S</th>
<th>I</th>
<th>R</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AXDX</td>
<td>14</td>
<td>46</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td></td>
<td>49</td>
<td>5</td>
<td>13</td>
<td></td>
</tr>
</tbody>
</table>

* p<0.001
* p=0.016

* Indicates significant difference (p<0.05) using Fishers Exact Test for contingency tables.

---

**LEGEND**

- **n** = Categorical Agreement (CA)
- **n** = Minor Error (MIE)
- **n** = Major Error (ME)
- **n** = Very Major Error (VME)

- Error (More Susceptible Than Reference)
- Error (More Resistant Than Reference)
Figure 3

**Computed Probabilities (p)**

<table>
<thead>
<tr>
<th>Combination</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>V2 All Samples &amp; DV2 All Samples</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>V2 All Samples &amp; AXDX All Samples</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>DV2 All Samples &amp; AXDX All Samples</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>V2 PAE &amp; DV2 PAE</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>V2 PAE &amp; AXDX PAE</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>DV2 PAE &amp; AXDX PAE</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>V2 All Samples &amp; V2 PAE</td>
<td>0.024</td>
</tr>
<tr>
<td>DV2 All Samples &amp; DV2 PAE</td>
<td>0.002</td>
</tr>
<tr>
<td>AXDX All Samples &amp; AXDX PAE</td>
<td>0.518</td>
</tr>
</tbody>
</table>

Computed probability (p) using Mann-Whitney U Test only shown on pair-wise combinations of AST methods in the ‘All Samples’ category and in ‘PAE’ category, not computed on other combinations.

**Abbreviations:**
- ABA = *A. baumannii*
- AST = antimicrobial susceptibility testing
- CIT = *Citrobacter* spp.
- ECO = *E. coli*
- ENT = *Enterobacter* spp.
- KLE = *Klebsiella* spp.
- PAE = *P. aeruginosa*
- PRO = *Proteus* spp.
- SMA = *S. marcescens*
- σ = standard deviation.
Computed probability (p) using Mann-Whitney U Test only shown on pair-wise combinations of AST methods in the ‘All Samples’ category and in ‘PAE’ category, not computed on other combinations.

**Abbreviations**: ABA=A. baumannii; AST=antimicrobial susceptibility testing; CIT=Citrobacter spp.; ECO=E. coli; ENT=Enterobacter spp.; KLE=Klebsiella spp.; PAE=P. aeruginosa; PRO=Proteus spp.; SMA=S. marcescens; σ=standard deviation.